Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Trial Profile

Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions
  • Acronyms TIRCON-EXT
  • Sponsors ApoPharma

Most Recent Events

  • 23 Apr 2018 Status changed from active, no longer recruiting to completed.
  • 17 Apr 2018 This trial has been completed in Germany (end date: 16 Mar 2018) , according to European Clinical Trials Database.
  • 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top